Article Sidebar
Views PDF: 141
EFFICACY OF LIPOSOMAL DOXORUBICIN ALONE IN THE TREATMENT OF OVARIAN CANCER AT HANOI ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the effectiveness of liposomal doxorubicin alone in the treatment of ovarian cancer at Hanoi Oncology Hospital. Subjects and methods: Using a retrospective descriptive design combined with prospective on 33 patients with histopathological diagnosis of ovarian carcinoma from 03/2022 to 10/2022 at Hanoi Oncology Hospital. Results: The overall response rate was 27.3%. In which there were no patients with complete response, 27.3% of patients with partial response, 30.3% with stable disease, 42.4% with progressive disease, 57.6% disease control rate. Median progression-free survival was 38.3 weeks. The patient had a change in overall health index and better CA125 index but not statistically significant. Conclusion: The liposomal doxorubicin regimen used to treat platinum-resistant recurrent ovarian cancer is an appropriate regimen in terms of efficacy and safety, and should be widely applied in clinical practice in specialized cancer treatment facilities. especially the base lines.
Article Details
Keywords
ovarian cancer, liposomal doxorubicin
References
2. Nguyễn Bá Đức, Đào Ngọc Phong (2008), Dịch tễ học bệnh ung thư, 19 – 21, Nhà xuất bản Y học.
3. Mutch D G, Orlando M, Goss T et al (2007), Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer, J Clin Oncol, 25(19), 2811-8.
4. Đồng Chí Kiên, Lê Thanh Đức (2021), Đánh giá kết quả điều trị bệnh nhân ung thư biểu mô buồng trứng tái phát kháng platinum bằng phác đồ liposomal doxorubicin tại bệnh viện K, Tạp chí Y học Việt Nam, 2(156), 156-159.
5. Coleman R L, Brady W E, McMeekin D S et al (2011), A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study, Gynecol Oncol, 122(1), 111-5.
6. Donovan H S, Ward S E, Sereika S M et al (2014), Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention, J Pain Symptom Manage, 47(2), 218-30.
7. Đặng Tiến Giang (2017), Đánh giá kết quả điều trị ung thư biểu mô buồng trứng tái phát tại bệnh viện K, Luận văn thạc sĩ y khoa, Trường Đại học Y Hà Nội.
8. Pfisterer J, Plante M, Vergote I et al (2006), Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, 24(29), 4699-707.